Successful treatment of renal failure in Goodpasture's syndrome

1971 ◽  
Vol 127 (5) ◽  
pp. 953-957 ◽  
Author(s):  
J. P. Hayslett
2010 ◽  
Vol 2010 ◽  
pp. 1-6 ◽  
Author(s):  
James Dahlgren ◽  
Marla Wardenburg ◽  
Trevor Peckham

We report a case of Goodpasture's syndrome following chronic low level and an acute, high level of exposure to crystalline silica. A 38-year-old male tilesetter was admitted to the emergency room with dyspnea and respiratory failure. He reported that his symptoms had developed over the previous week after inhaling a large amount of dust while dry-sanding and sweeping a silica-based product used to fill cracks in a cement floor. Over the following days, his pulmonary function declined and he developed acute renal failure. Tests of antiglomerular basement membrane antibody were positive and renal biopsy revealed global glomerulonephritis. He was diagnosed with Goodpasture's syndrome and treated with steroids, plasmapheresis, and hemodialysis. This man had a history of childhood asthma and a remote, one pack-year history of cigarette use. He used the flooring product for seven years prior to the inciting event, however, previous jobs had utilized significantly smaller amounts. Goodpasture's syndrome and other autoimmune diseases have been reported in association with silica exposure. The acute onset following high level silica exposure in this previously healthy man, suggest that clinicians should investigate silica exposure as a causal factor in cases of Goodpasture's syndrome.


2001 ◽  
Vol 34 (8) ◽  
pp. 1205-1210
Author(s):  
Yoshiaki Nishioka ◽  
Yasuhide Kanamoto ◽  
Hiroshige Kawano ◽  
Masanobu Miyazaki ◽  
Takashi Harada ◽  
...  

Nephron ◽  
1991 ◽  
Vol 57 (3) ◽  
pp. 381-382 ◽  
Author(s):  
A. Volpi ◽  
G. Battini ◽  
F. Conte ◽  
G.M. Ferrario ◽  
F. Giordano ◽  
...  

BMJ ◽  
1967 ◽  
Vol 4 (5571) ◽  
pp. 95-95 ◽  
Author(s):  
J F Munro ◽  
A M Geddes ◽  
W L Lamb

1977 ◽  
Vol 1 (24) ◽  
pp. 875-879 ◽  
Author(s):  
Rowan G. Walker ◽  
Anthony J. F. d'Apice ◽  
Gavin J. Becker ◽  
Priscilla Kincaid‐Smith ◽  
Peter W. T. Craswell

Nephron ◽  
1989 ◽  
Vol 52 (3) ◽  
pp. 285-285
Author(s):  
G. Salvidio ◽  
G. Garibotto ◽  
S. Saffioti ◽  
R. Pontremoli

2020 ◽  
Vol 9 (2) ◽  
pp. 455 ◽  
Author(s):  
Wisit Kaewput ◽  
Charat Thongprayoon ◽  
Boonphiphop Boonpheng ◽  
Patompong Ungprasert ◽  
Tarun Bathini ◽  
...  

Background: Goodpasture’s syndrome is a rare, life-threatening, small vessel vasculitis. Given its rarity, data on its inpatient burden and resource utilization are lacking. We conducted this study aiming to assess inpatient prevalence, mortality, and resource utilization of Goodpasture’s syndrome in the United States. Methods: The 2003–2014 National Inpatient Sample was used to identify patients with a principal diagnosis of Goodpasture’s syndrome. The inpatient prevalence, clinical characteristics, in-hospital treatment, end-organ failure, mortality, length of hospital stay, and hospitalization cost were studied. Multivariable logistic regression was performed to identify independent factors associated with in-hospital mortality. Results: A total of 964 patients were admitted in hospital with Goodpasture’s syndrome as the principal diagnosis, accounting for an overall inpatient prevalence of Goodpasture’s syndrome among hospitalized patients in the United States of 10.3 cases per 1,000,000 admissions. The mean age of patients was 54 ± 21 years, and 47% were female; 52% required renal replacement therapy, whereas 39% received plasmapheresis during hospitalization. Furthermore, 78% had end-organ failure, with renal failure and respiratory failure being the two most common end-organ failures. The in-hospital mortality rate was 7.7 per 100 admissions. The factors associated with increased in-hospital mortality were age older than 70 years, sepsis, the development of respiratory failure, circulatory failure, renal failure, and liver failure, whereas the factors associated with decreased in-hospital mortality were more recent year of hospitalization and the use of therapeutic plasmapheresis. The median length of hospital stay was 10 days. The median hospitalization cost was $75,831. Conclusion: The inpatient prevalence of Goodpasture’s syndrome in the United States is 10.3 cases per 1,000,000 admissions. Hospitalization of patients with Goodpasture’s syndrome was associated with high hospital inpatient utilization and costs.


Sign in / Sign up

Export Citation Format

Share Document